Infinity Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to producing innovative cancer treatments. IPI-549 is their clinical-stage immuno-oncology product candidate, which inhibits phosphoinositide-3-kinase-gamma and is currently being tested in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer, as well as Phase 1/1b clinical trials for the treatment of solid tumors. The firm has partnerships with Intellikine, Verastem, and PellePharm, as well as collaboration agreements with Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., and Arcus Biosciences, Inc.